Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brexpiprazole orally disintegrating tablet
- Development stage
- Approved
- Lead developer
- Otsuka Holdings
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Brexpiprazole is a second-generation (atypical) antipsychotic small molecule discovered by Otsuka and jointly developed with Lundbeck. It functions as a serotonin-dopamine activity modulator (SDAM), acting as a partial agonist at the dopamine D2 and D3 receptors and the serotonin 5-HT1A receptor, while also acting as an antagonist at 5-HT2A, 5-HT2B, and 5-HT7 receptors. The orally disintegrating tablet (ODT) formulation is specifically designed to dissolve rapidly in the oral cavity without the need for water, providing an alternative for patients who have difficulty swallowing conventional tablets or for whom adherence is a concern. It is indicated for the treatment of schizophrenia, as an adjunctive therapy for major depressive disorder, and for agitation associated with dementia due to Alzheimer's disease.
- Brand names
- Rexulti
- Other names
- brexpiprazole ODTl-Otsuka Pharmaceutical Co., Ltd.
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ADRA2C (α2C)HTR2B (5-Hydroxytryptamine Receptor 2B)DRD2 (Dopamine D2 Receptor)HTR7 (5-hydroxytryptamine receptor 7)DRD3 (Dopamine receptor D3)ADRA1B (α1B)
Beyond the preview
Go deeper on brexpiprazole orally disintegrating tablet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brexpiprazole orally disintegrating tablet.